Precision BioSciences to Participate in Upcoming August Investor Conferences
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced its participation in two upcoming investor conferences in August 2024. The company will attend the BTIG Biotechnology Conference on Monday, August 5, and the Sidoti Micro Cap Conference on Thursday, August 15.
At the Sidoti conference, Precision will give a virtual presentation from 10:00 am to 10:30 am ET. A live webcast of this presentation will be available on the company's website in the Investors section under Events & Presentations, with an archived replay accessible for about 30 days after the event.
Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision. The company's management team will be available for one-on-one meetings during both conferences.
Precision BioSciences (Nasdaq: DTIL), un'azienda avanzata nel campo dell'editing genetico, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno ad agosto 2024. L'azienda parteciperà alla BTIG Biotechnology Conference lunedì 5 agosto e alla Sidoti Micro Cap Conference giovedì 15 agosto.
Durante la conferenza Sidoti, Precision presenterà una relazione virtuale dalle 10:00 alle 10:30 ET. Una diretta web di questa presentazione sarà disponibile sul sito web dell'azienda nella sezione Investitori sotto Eventi & Presentazioni, con una registrazione archiviata accessibile per circa 30 giorni dopo l'evento.
Precision BioSciences utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genetico in vivo per modifiche genetiche complesse, inclusa l'eliminazione, l'inserzione e l'escissione di geni. Il team di gestione dell'azienda sarà disponibile per incontri one-to-one durante entrambe le conferenze.
Precision BioSciences (Nasdaq: DTIL), una empresa avanzada en edición genética, ha anunciando su participación en dos conferencias de inversores que se llevarán a cabo en agosto de 2024. La compañía asistirá a la BTIG Biotechnology Conference el lunes 5 de agosto y a la Sidoti Micro Cap Conference el jueves 15 de agosto.
En la conferencia Sidoti, Precision dará una presentación virtual desde las 10:00 hasta las 10:30 ET. Una transmisión en vivo de esta presentación estará disponible en el sitio web de la empresa en la sección de Inversores bajo Eventos & Presentaciones, con una repetición archivada accesible durante aproximadamente 30 días después del evento.
Precision BioSciences utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo para ediciones genéticas sofisticadas, incluida la eliminación, inserción y escisión de genes. El equipo de gestión de la empresa estará disponible para reuniones individuales durante ambas conferencias.
프리시전 바이오사이언스 (Nasdaq: DTIL)는 첨단 유전자 편집 회사로, 2024년 8월에 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 8월 5일 월요일에 열리는 BTIG 생명공학 컨퍼런스와 8월 15일 목요일에 열리는 시도티 마이크로 캡 컨퍼런스에 참석할 예정입니다.
시도티 컨퍼런스에서 프리시전은 동부 표준시 기준 오전 10시부터 10시 30분까지 온라인 발표를 진행할 것입니다. 이 발표의 실시간 웹캐스트는 회사 웹사이트의 투자자 섹션 내 이벤트 및 발표에서 이용할 수 있으며, 이벤트 후 약 30일 동안 아카이브된 재생이 가능합니다.
프리시전 바이오사이언스는 고유의 ARCUS® 플랫폼을 활용하여, 유전자 제거, 삽입 및 절제를 포함한 복잡한 유전자 편집을 위한 생체 내 유전자 편집 치료제를 개발하고 있습니다. 회사 경영진은 두 회의 모두에서 일대일 미팅을 위해 대기할 것입니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise avancée dans l'édition génétique, a annoncé sa participation à deux conférences pour investisseurs prévues en août 2024. L'entreprise assistera à la BTIG Biotechnology Conference le lundi 5 août et à la Sidoti Micro Cap Conference le jeudi 15 août.
Lors de la conférence Sidoti, Precision donnera une présentation virtuelle de 10h00 à 10h30 ET. Un webinaire en direct de cette présentation sera disponible sur le site web de l'entreprise dans la section Investisseurs sous Événements & Présentations, avec une rediffusion archivée accessible pendant environ 30 jours après l'événement.
Precision BioSciences utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génétique in vivo pour des modifications génétiques sophistiquées, y compris l'élimination, l'insertion et l'excision de gènes. L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles lors des deux conférences.
Precision BioSciences (Nasdaq: DTIL), ein fortschrittliches Unternehmen für Genbearbeitung, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im August 2024 bekannt gegeben. Das Unternehmen wird an der BTIG Biotechnology Conference am Montag, den 5. August, und an der Sidoti Micro Cap Conference am Donnerstag, den 15. August, teilnehmen.
Auf der Sidoti-Konferenz wird Precision von 10:00 bis 10:30 Uhr ET eine virtuelle Präsentation halten. Ein Live-Webcast dieser Präsentation wird auf der Website des Unternehmens im Bereich Investoren unter Veranstaltungen & Präsentationen verfügbar sein, und eine archivierte Wiederholung wird etwa 30 Tage nach der Veranstaltung zugänglich sein.
Precision BioSciences nutzt seine proprietäre ARCUS®-Plattform, um In-vivo-Gentherapien für komplexe Genbearbeitungen zu entwickeln, einschließlich Geneliminierung, Geneinfügung und Exzision. Das Management-Team des Unternehmens wird während beider Konferenzen für persönliche Gespräche zur Verfügung stehen.
- None.
- None.
BTIG Biotechnology Conference
Date: Monday, August 5, 2024
Sidoti Micro Cap Conference
Date: Thursday, August 15, 2024
Time: 10:00 am – 10:30 am ET
Format: Virtual
A live webcast of the Sidoti presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcast will be available for approximately 30 days following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731815341/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When is Precision BioSciences (DTIL) participating in the BTIG Biotechnology Conference?
What time is Precision BioSciences (DTIL) presenting at the Sidoti Micro Cap Conference?
Where can I watch the webcast of Precision BioSciences' (DTIL) Sidoti conference presentation?
How long will the replay of Precision BioSciences' (DTIL) Sidoti presentation be available?
What is the main focus of Precision BioSciences' (DTIL) gene editing technology?
